Skip to main content
Opthea Ltd logo

Opthea Ltd — Investor Relations & Filings

Ticker · OPT ISIN · US68386J2087 LEI · 549300Q5FMFDLP46SF83 ASX Manufacturing
Open in API
Filings indexed 1,390 across all filing types
Latest filing 2019-11-19 Major Shareholding Noti…
Country AU Australia
Listing ASX OPT

About Opthea Ltd

https://opthea.com/

Opthea is a clinical-stage biopharmaceutical company focused on developing novel therapies for vision-threatening retinal diseases, particularly wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The company's lead product candidate, sozinibercept, is a first-in-class biologic 'trap' inhibitor targeting Vascular Endothelial Growth Factors C and D (VEGF-C and VEGF-D). Sozinibercept is being developed for administration in combination with standard-of-care anti-VEGF-A therapies. This dual-pathway inhibition aims to deliver superior visual outcomes by more comprehensively blocking the mechanisms that contribute to disease progression, addressing the limitations of current treatments that only target VEGF-A. The therapy is being evaluated in late-stage pivotal clinical trials for wet AMD.

Recent filings

Filing Released Lang Actions
Change in substantial holding 18 pages 109.7KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 Notice of change of interests of substantial holder under Corporations Law Section 671B. It details changes in voting power and relevant interests of a substantial holder (Bank of America Corporation and related bodies corporate) in the company Opthea Ltd. The document includes dates of changes, nature of changes, and securities affected. This type of filing is a notification of changes in significant share ownership levels, which matches the definition of Major Shareholding Notification (MRQ). The document is lengthy and contains detailed shareholding changes, not just an announcement or summary, confirming it is the actual notification filing.
2019-11-19 English
Opthea Clinical Data Published in Leading Ophthalmic Journal 3 pages 98.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX and media release dated 29 October 2019 from Opthea Limited announcing the publication of first-in-human clinical data for their drug OPT-302 in a leading ophthalmic journal. It discusses clinical trial results, scientific details about the drug and disease, and includes forward-looking statements and investment risk disclosures. There are no financial statements, regulatory certifications, voting results, or management changes. The document is a press release announcing clinical trial data publication rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a general company announcement about clinical data publication, best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not fit other specific categories.
2019-10-28 English
Ceasing to be a substantial holder 9 pages 334.4KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 605 filed under the Corporations Act 2001, titled 'Notice of ceasing to be a substantial holder.' It details changes in relevant interests of a substantial holder, including acquisitions and disposals of shares, and includes prescribed information about securities lending agreements. The document is regulatory in nature, reporting changes in significant share ownership levels and compliance with disclosure requirements. It does not contain financial statements, management discussion, or earnings data. Therefore, it fits the definition of a Major Shareholding Notification (MRQ). The document length and detail support a confident classification.
2019-10-28 English
Becoming a substantial holder 24 pages 560.1KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 603 Notice of Initial Substantial Holder filed under the Corporations Act 2001. It details the substantial shareholding of Credit Suisse Holdings (Australia) Limited in Opthea Limited, including voting power, relevant interests, registered holders, consideration paid for shares, and associates. This type of filing is a notification of a major shareholding level crossing a threshold, which is typical for substantial holder notices. It is not an annual report, earnings release, or any other financial report. It is specifically a major shareholding notification.
2019-10-23 English
Annual Report 2019 68 pages 3.6MB
Annual Report Classification · 100% confidence The document is titled '2018-2019 Annual Report' and contains detailed sections typical of an annual report, including a message from the Chairman and CEO, Directors' Report, Management Team, Financial Report, and Corporate Information. It discusses the company's principal activities, clinical trial updates, financial performance, and shareholder information. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. There is no indication that this is merely a notice of report publication or a certification. Therefore, this document fits the definition of an Annual Report (10-K).
2019-10-17 English
Appendix 4G and Corporate Governance Statement 2019 22 pages 953.5KB
Governance Information Classification · 95% confidence The document is titled 'Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations' and references ASX Listing Rules 4.7.3 and 4.10.3. It is a detailed disclosure form related to corporate governance practices, indicating compliance with ASX Corporate Governance Council recommendations for the financial year ended 30 June 2019. The document includes references to the corporate governance statement, URLs to governance charters, and explanations of compliance or non-compliance with governance principles. It is not the corporate governance statement itself but a key to disclosures and a verification tool submitted alongside the annual report as required by ASX rules. The document does not contain financial statements or management discussion of financial results, nor is it an announcement or a brief summary. It is a regulatory filing specifically related to governance disclosures. Therefore, the most appropriate classification is Governance Information (CGR).
2019-10-17 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.